Having confirmed in vitro binding of our CD47-blocking agents, we next characterized the impact of intratumoral administration of these rNDVs in vivo in a B16-F10 melanoma model since we observed the highest level of CD47 upregulation and transgene expression following NDV infection in B16-F10 cells (Figure 1A). The gene discussed is CD47; the disease is melanoma.